Bristol-Myers Says Lung Cancer Drug Combination Met Trial Goal
- Company is testing drug in tumors with lots of mutations
- Data are key step in high-stakes race between drugmakers
Photographer: David Paul Morris/Bloomberg
This article is for subscribers only.
Bristol-Myers Squibb Co.’s drug cocktail for lung cancer patients with highly mutated tumors met a major goal of a late-stage study, an important step as the company tries to get the therapy used in newly diagnosed patients.
In the 299-patient trial, patients with advanced lung cancer who got a combination of Bristol-Myers’ drugs Yervoy and Opdivo were 42 percent less likely to have their disease progress, compared to patients on chemotherapy alone, according to data presented at the American Association for Cancer Research meeting in Chicago. Bristol-Myers said in February that the trial succeeded, but didn’t provide specifics.